TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8879766

Group type: EXPERIMENTAL
Intervention: Exposure to cytomegalovirus (CMV) from the donated organ
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Patients with bacteremia
Number of subjects: 146

Group type: COMPARATOR
Intervention: Patients without bacteremia
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Donor CMV seropositivity
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Age younger than 16 years
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Major abdominal operation after transplantation (excluding retransplantation)
Number of subjects: 146
Study: 1991685

Group type: EXPERIMENTAL
Intervention: Combined modality (CM) treatment with Cisplatin 50 mg IV weekly during radiotherapy.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Radiotherapy (RT) without chemotherapy.
Number of subjects: 83
Study: 6663643

Group type: EXPERIMENTAL
Intervention: Structured couples treatment program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study: 31430249

Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) for estimating AUC0-12 of mycophenolic acid (MPA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) for estimating AUC0-12 of acyl glucuronide metabolite (AcMPAG)
Number of subjects: 45
Study: 29570535

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation with testosterone enanthate injections at 2-week intervals during bed rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized aerobic and resistance training 6 days per week in a horizontal body position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized measures targeting a wide range of physiologic systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized diet provided to ensure consistent nutritional intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily measurements of vital signs, body weight, and fluid intake and output
Number of subjects: 0
Study: 28931527

Group type: EXPERIMENTAL
Intervention: e‐cigarette with nicotine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: e‐cigarette without nicotine
Number of subjects: 33

Group type: COMPARATOR
Intervention: sham control
Number of subjects: 33
Study: 26239595

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 34
Study: 22075412

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 800
Study: 21632697

Group type: EXPERIMENTAL
Intervention: 4% icodextrin solution (Adept)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 498
Study: 18292445

Group type: EXPERIMENTAL
Intervention: Postoperative celecoxib (2 celecoxib 200 mg p.o. after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2 and #3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perioperative celecoxib (2 celecoxib 200 mg p.o. 30‐90 min before surgery, and two placebos after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2, and #3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (two placebos orally before and after surgery, as well as one placebo BID for 3 days after surgery)
Number of subjects: 120
Study: 16548286

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered prior to anesthesia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered during transanesthesia
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 3
Study: 12656882

Group type: EXPERIMENTAL
Intervention: beta-tricalciumphosphate (beta-TCP) with platelet-rich plasma (PRP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: beta-tricalciumphosphate (beta-TCP) without platelet-rich plasma (PRP)
Number of subjects: 39
Study: 11191783

Group type: EXPERIMENTAL
Intervention: Fluid replacement (200 or 250 ml of warm water at approximately 35 degrees C) during light exercise (L/F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF) during light exercise (L/NF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid replacement (F) during heavy exercise (H)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF) during heavy exercise (H/NF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid replacement (F) during light exercise (L)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF) during light exercise (L)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid (NF) during heavy exercise (H)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid replacement during light exercise (L/F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid during light exercise (L/NF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluid replacement during heavy exercise (H/F)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No fluid during heavy exercise (H/NF)
Number of subjects: 8
Study: 9097062

Group type: EXPERIMENTAL
Intervention: Outpatient mental health visits to primary care providers
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Outpatient mental health visits to specialty mental health providers
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Visits to nonpsychiatrist medical specialists
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Service utilization based on frequency of panic attacks
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Service utilization based on severity of impairment
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Estimated expenditure for panic episode
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Median estimated expenditures for primary care and specialty mental health services
Number of subjects: 391
Study: 8255440

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) - L‐leucine 12 g, L‐isoleucine 6 g, L‐valine 6 g daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 126
Study: 3515261

Group type: EXPERIMENTAL
Intervention: Intramuscular ritodrine followed by oral ritodrine treatment and bed rest
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo and bed rest
Number of subjects: 99
Study: 30157364

Group type: EXPERIMENTAL
Intervention: HSC+LC
Number of subjects: 186

Group type: COMPARATOR
Intervention: LC
Number of subjects: 186

Group type: COMPARATOR
Intervention: HSC
Number of subjects: 186
Study: 26407878

Group type: EXPERIMENTAL
Intervention: Fentanyl low dose (12 μg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fentanyl moderate dose (24 μg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propofol (for anaesthesia induction)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 25630513

Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 748

Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 748
Study: 23043946

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 234

Group type: COMPARATOR
Intervention: GnRH
Number of subjects: 234
Study: 20379004

Group type: EXPERIMENTAL
Intervention: Drug alteration (DA) group
Number of subjects: 390

Group type: COMPARATOR
Intervention: Single AA patients
Number of subjects: 390
Study: 17943420

Group type: EXPERIMENTAL
Intervention: Nalbuphine (2.5, 5, 10, or 20 mg)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Nalbuphine (ED(50) estimated at 5.85 mg)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 or 0.4 mg, ED(50) estimated at 0.5 mg)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Nalbuphine and Naloxone (in combination)
Number of subjects: 304
Study: 15723964

Group type: EXPERIMENTAL
Intervention: Potassium chloride (96 mmol/d for 1 week)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Potassium citrate (96 mmol/d for 1 week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of potassium chloride and potassium citrate
Number of subjects: 14
Study: 12458845

Group type: EXPERIMENTAL
Intervention: Daunorubicin 0.02% applied subconjunctivally for 3 minutes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Distilled water applied for 3 minutes
Number of subjects: 24
Study: 10624842

Group type: EXPERIMENTAL
Intervention: Positive group focusing on positive aspects of information
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Negative group focusing on negative aspects of information
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group focusing on an unrelated disease
Number of subjects: 104
Study: 8614916

Group type: EXPERIMENTAL
Intervention: Carotid PTA
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 11
Study: 2006724

Group type: EXPERIMENTAL
Intervention: midazolam/flumazenil (15 mg midazolam, 0.5 mg flumazenil after 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo/flumazenil (sodium chloride instead of midazolam, 0.5 mg flumazenil after 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo/placebo (sodium chloride instead of midazolam and flumazenil)
Number of subjects: 12
Study: 397411

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31030363

Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard of care for gout flare
Number of subjects: 75
Study: 28878376

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 60
Study: 24585502

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (ZES)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Xience V everolimus-eluting stents (EES)
Number of subjects: 1033
Study: 23635869

Group type: EXPERIMENTAL
Intervention: Kava (120/240 mg of kavalactones per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 17456241

Group type: EXPERIMENTAL
Intervention: Early intervention group (educational programme delivered at baseline)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Delayed intervention group (educational programme delivered at 6 months)
Number of subjects: 23
Study: 14742376

Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine combined with 0.1 mg/h morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1% ropivacaine combined with 0.1 mg/h morphine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine and 0.1% ropivacaine
Number of subjects: 50
Study: 10783450

Group type: EXPERIMENTAL
Intervention: Emla (2.5% lignocaine and 2.5% prilocaine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lignocaine gel alone
Number of subjects: 10
Study: 9073002

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 1,000 microg x day‐1 for 6 weeks
Number of subjects: 40
Study: 7923728

Group type: EXPERIMENTAL
Intervention: Reinforcing manipulation (RFM)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reducing manipulation (RDM)
Number of subjects: 78
Study: 3018603

Group type: EXPERIMENTAL
Intervention: Enalapril (10‐20 mg b.i.d.)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined enalapril (10‐20 mg b.i.d.) and hydrochlorothiazide (25‐50 mg b.i.d.)
Number of subjects: 39
Study: 31679945

Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 882

Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 882
Study: 30236517

Group type: EXPERIMENTAL
Intervention: Mean nighttime wind turbine noise (WTN) exposure during pregnancy
Number of subjects: 135795

Group type: EXPERIMENTAL
Intervention: High exposure categories of ≥ 42 dB outdoor WTN or ≥ 15 dB indoor LF WTN
Number of subjects: 135795
Study: 27416045

Group type: EXPERIMENTAL
Intervention: Budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks
Number of subjects: 546
Study: 25539654

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg twice daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 21819487

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20112485

Group type: EXPERIMENTAL
Intervention: 5-step manipulation and traction (treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traction (control group)
Number of subjects: 120
Study: 17484080

Group type: COMPARATOR
Intervention: Intravenous indomethacin (0.2 mg/kg at 12‐hour intervals)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (10 mg/kg initial dose, followed by two doses of 5 mg/kg each after 24 and 48 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous indomethacin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension
Number of subjects: 21
Study: 15047685

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (<10% carbohydrate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-fat diet (<30% fat)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet
Number of subjects: 13
Study: 11818602

Group type: EXPERIMENTAL
Intervention: Sedation with adjunct hypnosis
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard intravenous conscious sedation
Number of subjects: 161
Study: 9470469

Group type: EXPERIMENTAL
Intervention: Training on a wobble board for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Training on a wobble board
Number of subjects: 48
Study: 7610512

Group type: EXPERIMENTAL
Intervention: Cytokine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nephrectomy
Number of subjects: 0
Study: 2378717

Group type: EXPERIMENTAL
Intervention: Esophagography
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Esophagoscopy
Number of subjects: 182
Study: 365126

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study: 30616547

Group type: EXPERIMENTAL
Intervention: BITS7201A (300 mg SC, 750 mg IV, 150 mg SC, 300 mg SC, 600 mg SC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BITS7201A (150 mg SC, 300 mg SC, 600 mg SC)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: BITS7201A
Number of subjects: 41
Study: 28183284

Group type: EXPERIMENTAL
Intervention: QbTest
Number of subjects: 86
Study: 25287767

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard therapy without intra-aortic balloon pump
Number of subjects: 600
Study: 23820879

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program for 12 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 86
Study: 21188406

Group type: EXPERIMENTAL
Intervention: Ropinirole IR (up to 4 mg/day)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Ropinirole IR
Number of subjects: 231
Study: 19810583

Group type: EXPERIMENTAL
Intervention: Formalin exposure during gross anatomy laboratory dissection class (2 hours)
Number of subjects: 20
Study: 17294136

Group type: EXPERIMENTAL
Intervention: Facilitated PAD intervention (individual meeting with a trained facilitator)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Control group (written materials about PADs)
Number of subjects: 469
Study: 15878000

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 301

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 301
Study: 11328289

Group type: EXPERIMENTAL
Intervention: Intensified therapy (third block of late intensification)
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: Intensified therapy
Number of subjects: 2090

Group type: COMPARATOR
Intervention: Control group (not randomized to the third block)
Number of subjects: 2090
Study: 9617650

Group type: EXPERIMENTAL
Intervention: Videofeedback training
Number of subjects: 0
Study: 7938915

Group type: EXPERIMENTAL
Intervention: Constant work rate exercise (CWE) at 76% of maximum work rate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Maximal incremental exercise (MIE)
Number of subjects: 10
Study: 3282214

Group type: EXPERIMENTAL
Intervention: Ceftazidime (CAZ)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Ceftazidime + Vancomycin (CAZ + vancomycin)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Cephalothin, Carbenicillin and Gentamicin (KCG)
Number of subjects: 206

Group type: COMPARATOR
Intervention: KCG
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: CAZ or CAZ + vancomycin
Number of subjects: 206
Study: 27911988

Group type: EXPERIMENTAL
Intervention: Mirabegron (25-50 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Solifenacin (2.5-5 mg)
Number of subjects: 148
Study: 27658130

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (2.4 g daily for 1 month)
Number of subjects: 39
Study: 24793938

Group type: EXPERIMENTAL
Intervention: BPZE1 vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 24209423

Group type: EXPERIMENTAL
Intervention: Multi-component intervention (organisational, environmental with height-adjustable workstations, and individual behavioural strategies)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual practice control group
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 320
Study: 20542324

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) using a rush protocol with roasted peanut for 7 days
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 23
Study: 18382682

Group type: EXPERIMENTAL
Intervention: Fuzzy prediction measure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk reduction calculation
Number of subjects: 0
Study: 16203884

Group type: EXPERIMENTAL
Intervention: Open operative treatment
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Functional brace postoperatively
Number of subjects: 800

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 800
Study: 12519844

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily for 3 months, then 1000 mg twice daily for 3 months; n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Ethinyl estradiol-cyproterone acetate (EE-CA; n = 9)
Number of subjects: 17
Study: 10930893

Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg b.d per 7 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Activated charcoal (400 mg b.d per 7 days)
Number of subjects: 34
Study: 8980155

Group type: EXPERIMENTAL
Intervention: L-Arginine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Molsidomine
Number of subjects: 0
Study: 1426824

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 to 2 mg IV) alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Terlipressin (1 to 2 mg IV) combined with nitroglycerin infusion (25 micrograms/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Terlipressin alone
Number of subjects: 19
Study: 6140440

Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption (up to 80 g daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: No alcohol for 4 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: No alcohol for the first 3 days, then resumed alcohol consumption from day 4 to 7
Number of subjects: 16
Study: 31035190

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/day at bedtime)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29025064

Group type: COMPARATOR
Intervention: Cholera vaccination only
Number of subjects: 429995

Group type: COMPARATOR
Intervention: Cholera vaccination plus behaviour change (promotion of hand-washing with soap plus drinking water chlorination)
Number of subjects: 429995

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429995
Study: 25472768

Group type: EXPERIMENTAL
Intervention: Insulin therapy (long/intermediate acting)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Insulin therapy (premixed)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Insulin therapy (basal-bolus)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 211
Study: 23434503

Group type: EXPERIMENTAL
Intervention: Switch to aripiprazole
Number of subjects: 187

Group type: COMPARATOR
Intervention: Stay on olanzapine, quetiapine, or risperidone
Number of subjects: 187
Study: 19549615

Group type: EXPERIMENTAL
Intervention: Eccentric loading exercises (ELE)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Prolotherapy injections of hypertonic glucose with lignocaine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combined treatment (ELE + prolotherapy)
Number of subjects: 43
Study: 19165197

Group type: EXPERIMENTAL
Intervention: Proficient mismatch repair (pMMR)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Deficient mismatch repair (dMMR) caused by hypermethylation of the MLH1 promoter
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Total deficient mismatch repair (dMMR)
Number of subjects: 820
Study: 16696522

Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 microg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12689948

Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 30